Magazine Article | September 1, 2020

From Diligence To Execution — Tim Wright's Approach To Leading MiMedx

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

“The Bad News Keeps Coming For MiMedx And Its New Auditor EY,” read the July 3, 2018, MarketWatch headline.

The publicly traded biopharma faced an accounting scandal involving three former executives (i.e., CEO, COO, and CFO), and consequently, would have to restate more than five years of financials. And more trouble would soon follow. It makes you wonder what type of person would want to take on leading a company that was facing such significant reputational challenges. How about 36-year biopharma veteran Tim Wright?

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: